Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TALS

TALS - Talaris Therapeutics, Inc. Stock Price, Fair Value and News

$2.72-0.02 (-0.73%)
Market Closed

Price Targets

TALS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TALS Price Action

TALS RSI Chart

TALS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TALS Valuation

Market Cap

73.5M

Price/Earnings (Trailing)

-0.83

Price/Free Cashflow

-0.85

TALS Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

TALS Fundamentals

TALS Revenue

TALS Earnings

Earnings (TTM)

-88.5M

Earnings Growth (Yr)

-32.05%

Earnings Growth (Qtr)

-0.53%

TALS Profitability

Return on Equity

-34.13%

Return on Assets

-32.85%

Free Cashflow Yield

-117.45%

TALS Investor Care

Shares Dilution (1Y)

0.20%

Diluted EPS (TTM)

-3.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
Get all data in R, Python etc through our Historical Stock Data APIs

About Talaris Therapeutics, Inc.

TALS
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
 CEO
 WEBSITEhttps://talaristx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES84

Talaris Therapeutics, Inc. Frequently Asked Questions

TALS is the stock ticker symbol of Talaris Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Jul 31 2025, market cap of Talaris Therapeutics, Inc. is 73.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TALS's fair value in chart for subscribers.

The fair value guage provides a quick view whether TALS is over valued or under valued. Whether Talaris Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Talaris Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TALS.